Skip to content
Other

Remainder of Fiscal Year 2025

Amgen Remainder of Fiscal Year 2025 increased by 200.0% to $2.7B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.9%, from $3.1B to $2.7B.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
Metric ID: remainder_2025

Historical Data

15 periods
 Q2 '21Q3 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$1.2B$600M$1.9B$1.3B$600M$2.1B$1.4B$700M$3.6B$2.4B$1.2B$3.1B$2B$900M$2.7B
QoQ Change-50.0%+216.7%-31.6%-53.8%+250.0%-33.3%-50.0%+414.3%-33.3%-50.0%+158.3%-35.5%-55.0%+200.0%
YoY Change+8.3%+0.0%+10.5%+7.7%+16.7%+71.4%+71.4%+71.4%-13.9%-16.7%-25.0%-12.9%
Range$600M$3.6B
CAGR+26.1%
Avg YoY Growth+15.8%
Median YoY Growth+8.0%

Remainder of Fiscal Year 2025 at Other Companies

Frequently Asked Questions

What is Amgen's remainder of fiscal year 2025?
Amgen (AMGN) reported remainder of fiscal year 2025 of $2.7B in Q1 2026.
How has Amgen's remainder of fiscal year 2025 changed year-over-year?
Amgen's remainder of fiscal year 2025 decreased by 12.9% year-over-year, from $3.1B to $2.7B.